Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Greco MFD, Minelli C, Sheehan NA, Thompson JR
Supplementary information Source data Rights and permissions Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made
The pathophysiology of DGP is postulated to involve hyperglycemia or extreme hypoglycemia-induced impairment of gastrointestinal (GI) vagal dysfunction from the loss of Cajals interstitial cells and enteric glial cells
Injection site reactions (erythema, pruritus, swelling) occur in 1.4-2.4% of patients using subcutaneous formulations and are well-documented, localized effects
In a phase 3 ATTAIN-1 trial , adults who took orforglipron for 72 weeks lost an average of 7.5%11.2%
